Thyme Care Secures $97M Series D to Expand AI-Driven Oncology Solutions
Thyme Care has announced a $97 million Series D funding round, backed by strategic investors such as CVS Health Ventures and JPMorgan Chase, announced in a press release. This funding brings Thyme Care's total capital raised to $275 million.
The company, which manages over $5 billion in oncology spending and serves 8 million people nationwide, aims to dismantle barriers in cancer care through an AI orchestration layer. This technology reduces cognitive overload on care teams and accelerates stakeholder integration, providing timely and personalized support to patients.
With new contracts in Medicare, commercial, and employer sectors, Thyme Care is positioned to expand its national scale and improve outcomes in oncology care. The funding will support the company's mission to build an integrated oncology infrastructure focused on value, accountability, and enhancing patient experiences.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 19 Knit Health raises $35 million to roll out its healthcare world model Nov 19 Banner Health invests in Layer Health and moves its clinical registries onto its AI platform Nov 19 Half of Koreans who changed medication on AI advice had side effects, survey finds Nov 19 Isomorphic Labs and MSD team up to design cancer drugs with AI Nov 19 Boltz raises $110 million to build AI models for drug designMore from Funding
Nov 20 hackajob raises $10 million to expand Archer, its AI recruiting agent Nov 20 Protesters rally against Anthropic in New York and San Francisco on its stock market debut Nov 19 Anthropic's IPO could channel about $156 billion to charity, TechCrunch estimates Nov 19 Sierra reportedly in talks to raise at a $30 billion valuation Nov 19 Everful raises $48.5 million to build AI infrastructure for global commerceAI Funding Brief
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Pathos AI Raises $237 Million at $3 Billion Valuation
Vera Health raises $28.5M for clinical AI search
Lumeris launches Tom Health to extend primary care with AI
Orakl Oncology Raises $34 Million to Predict Cancer Drug Response With AI
Hone Health raises $228 million to expand AI-enabled longevity care
Daily AI Brief: the AI news that matters, in your inbox.